Quantcast

Positive Top Line Results From Clinical Trial for Diagnosis of Basal Cell Carcinoma Using VivoSight OCT

March 27, 2014

ORPINGTON, England, March 27, 2014 /PRNewswire/ –

Michelson Diagnostics, the UK based medical device company focused on multi-beam
Optical Coherence Tomography (‘OCT’) technology, announces positive top line results from
the successfully completed multi-centre, prospective clinical trial for the diagnosis of
basal cell carcinoma using VivoSight OCT.

In the study, over 250 patients with clinically suspicious lesions for basal cell
carcinoma were scanned at six centres in Germany. In each case, diagnosis using VivoSight
OCT was compared with standard clinical diagnosis with and without dermoscopy. All results
were verified by the gold standard of biopsy and histological analysis.

Papers by Professor Dr. med. Julia Welzel, Dr. med. Martina Ulrich discussing the
results from the clinical study were presented at the American Academy of Dermatology’s
72nd Annual Meeting (AAD) in Denver, Colorado, on Tuesday, 25 March 2014.

Dr Ulrich concluded in her presentation that: “VivoSight enabled a statistically
significant improvement in the specificity and Negative Predictive Value (NPV) of Basal
Cell Carcinoma diagnosis over both clinical and dermoscopy on this cohort of challenging
pink patches. So many biopsies can be rendered unnecessary, with VivoSight OCT, patients
can instead be treated non-invasively.”

Dr Gordon McKenzie, Director of Clinical Development at Michelson Diagnostics, said:
“We are delighted that Dr Ulrich and her colleagues were able to present these exciting
results with such clear implications for clinical practice in terms of the avoidance of
biopsy in many situations.”

Jon Holmes, CEO of Michelson Diagnostics, added: “The positive results from our study
clearly demonstrate the clinical benefits of using our VivoSight OCT system in the
diagnosis and monitoring of basal cell carcinoma. We believe that VivoSight has the
potential to become the standard of care for the non-invasive diagnosis and monitoring of
certain diseases and conditions that affect the skin, and in particular non-melanoma skin
cancers. We look forward to releasing the full data in due course.”

The full results will be published in a leading peer review journal later this year.

Notes to editors

About Michelson Diagnostics and the VivoSight System

Michelson Diagnostics has developed a world-leading, patented, medical imaging
technology, known as multi-beam Optical Coherence Tomography (‘OCT’), that uses an
advanced laser scanner to ‘see’ into tissue with unprecedented image resolution and
quality of image. Multi-beam OCT has many potential clinical applications, but we are
currently focusing on dermatology.

Our vision is for our VivoSight OCT system to become the standard of care for the
non-invasive diagnosis and monitoring of certain diseases and conditions that affect
cutaneous and epithelial linings of the body. We currently generate revenues from our
first commercial application of VivoSight, which is in the diagnosis of non-melanoma skin
cancer (NMSC).

VivoSight has regulatory clearance in Europe, USA and Australia, for use by trained
clinicians in their assessment of the patient’s medical condition. We have launched
VivoSight in Germany where the VivoSight scan is reimbursed for patients with private
healthcare insurance.

The Company, based in Orpington, Kent, was founded in 2006 and has 18 employees. It
has sales offices in Germany and USA. It has been supported through funding from a
syndicate of Venture Capital, corporate and private investors including Octopus, Catapult
Ventures and Angel Investors.

For more information about Michael Diagnostics, see

http://www.michelsondiagnostics.com.

For further information

        Michelson Diagnostics
        Jon Holmes, Chief Executive Officer
        Tel: +44(0)20-8308-1695

        FTI Consulting
        Simon Conway / Mo Noonan / Victoria Foster Mitchell
        Tel: +44(0)20-3727-1000

SOURCE Michelson Diagnostics


Source: PR Newswire



comments powered by Disqus